Comparison of Atorvastatin 5 and 20 mg/d for Reducing F-18 Fluorodeoxyglucose Uptake in Atherosclerotic Plaques on Positron Emission Tomography/Computed Tomography: A Randomized, Investigator-Blinded, Open-Label, 6-Month Study in Japanese Adults Scheduled for Percutaneous Coronary Intervention

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2337-2347

  Ishii, Hideki ^a   Nishio, Masami ^b   Takahashi, Hiroshi ^c   Aoyama, Toru ^c   Tanaka, Miho ^c   Toriyama, Takanobu ^c   Tamaki, Tsuneo ^b   Yoshikawa, Daiji ^a   Hayashi, Mutsuharu ^a   Amano, Tetsuya ^a   Matsubara, Tatsuaki ^d   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nagoya PET Imaging Center   (Japan)

^c NAGOYA KYORITSU HOSPITAL   (Japan)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Lipids; Plaque; Positron emission tomography; Statin

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FLUORODEOXYGLUCOSE F 18; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; TRIACYLGLYCEROL;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCENDING AORTA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FEMORAL ARTERY; FOLLOW UP; HUMAN; JAPANESE; LIVER TOXICITY; MALE; MUSCULOSKELETAL DISEASE; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STABLE ANGINA PECTORIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; ANTICHOLESTEREMIC AGENTS; AORTA; ATHEROSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; FEMORAL ARTERY; FLUORODEOXYGLUCOSE F18; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 79951824367     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.12.001     Document Type: Article

References (37)

1. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992, 326:242-250.
2. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
4. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
5. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
6. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
7. Hansson G.K., Robertson A.K., Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006, 1:297-329.
8. Stoll G., Bendszus M. Inflammation and atherosclerosis: Novel insights into plaque formation and destabilization. Stroke 2006, 37:1923-1932.
9. Ogawa M., Ishino S., Mukai T., et al. (18)F-FDG accumulation in atherosclerotic plaques: Immunohistochemical and PET imaging study. J Nucl Med 2004, 45:1245-1250.
10. Tawakol A., Migrino R.Q., Hoffmann U., et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2005, 12:294-301.
11. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105:2708-2711.
12. Aziz K., Berger K., Claycombe K., et al. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation 2008, 117:2061-2070.
13. Cortellaro M., Cofrancesco E., Arbustini E., et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: The ATROCAP study. Thromb Haemost 2002, 88:41-47.
14. Dunmore B.J., McCarthy M.J., Naylor A.R., Brindle N.P. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg 2007, 45:155-159.
15. Raffel O.C., Tearney G.J., Gauthier D.D., et al. Relationship between a systemic inflammatory marker, plaque inflammation, and plaque characteristics determined by intravascular optical coherence tomography. Arterioscler Thromb Vasc Biol 2007, 27:1820-1827.
16. Jaffer F.A., Libby P., Weissleder R. Molecular imaging of cardiovascular disease. Circulation 2007, 116:1052-1061.
17. Miyagi M., Ishii H., Murakami R., et al. Impact of long-term statin treatment on coronary plaque composition at angiographically severe lesions: A nonrandomized study of the history of long-term statin treatment before coronary angioplasty. Clin Ther 2009, 31:64-73.
18. Miyagi M., Ishii H., Murakami R., et al. Impact of renal function on coronary plaque composition. Nephrol Dial Transplant 2010, 25:175-181.
19. Taylor A.J., Kent S.M., Flaherty P.J., et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002, 106:2055-2060.
20. Ii M., Losordo D.W. Statins and the endothelium. Vascul Pharmacol 2007, 46:1-9.
21. Shaw S.M., Fildes J.E., Yonan N., Williams S.G. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009, 112:4-12.
22. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933-1935.
23. Tamura A., Watanabe T., Nasu M. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circ J 2003, 67:816-820.
24. Rudd J.H., Myers K.S., Bansilal S., et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007, 50:892-896.
25. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48:1825-1831.
26. Rudd J.H., Myers K.S., Bansilal S., et al. Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008, 49:871-878.
27. Tawakol A., Migrino R.Q., Bashian G.G., et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48:1818-1824.
28. Armitage P., Berry G., Matthews J.N. Statistical Methods in Medical Research 2002, Blackwell Scientific Ltd, Oxford, UK. 4th ed.
29. Stigler S.M. Francis Galton's account of the invention of correlation. Statist Sci 1989, 4:73-79.
30. Kinlay S., Timms T., Clark M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002, 89:1205-1207. Vascular Basis Study Group.
31. Turner R.C., Millns H., Neil H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
32. Mueller C., Buettner H.J., Hodgson J.M., et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002, 105:1412-1415.
33. Goldstein J.A., Chandra H.R., O'Neill W.W. Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. Am J Cardiol 2005, 96:56-60.
34. Ishii H., Toriyama T., Aoyama T., et al. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis. Circ Cardiovasc Interv 2009, 2:513-518.
35. Nissen S.E. High-dose statins in acute coronary syndromes: Not just lipid levels. JAMA 2004, 292:1365-1367. [published correction appears in JAMA. 2005;293:42].
36. Paffen E., DeMaat M.P. C-reactive protein in atherosclerosis: A causal factor?. Cardiovasc Res 2006, 71:30-39.
37. Tani S., Dimayuga P.C., Anazawa T., et al. Aberrant antibody responses to oxidized LDL and increased intimal thickening in apoE-/- mice exposed to cigarette smoke. Atherosclerosis 2004, 175:7-14.